{"entity":{"id":"nct07620574","kind":"trial","name":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","aka":[],"tldr":"A phase 3 trial of cabozantinib, zanzalintinib, atezolizumab, nivolumab and other drugs in colorectal cancer, run by Exelixis, now recruiting.","summary":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study is a phase 3, interventional study registered as NCT07620574 by Exelixis, with a registry enrolment figure of 5000 participants, started 2026-07-30 and due to reach its primary completion in 2030-05-31. Interventions recorded: Cabozantinib; Zanzalintinib; Atezolizumab; Nivolumab; Abiraterone; Prednisone; Enzalutamide. Conditions listed: Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET); Extra-Pancreatic NET (epNET); Hepatocellular Carcinoma (HCC); Differentiated Thyroid Cancer (DTC); Non-Clear Cell Renal Cell Carcinoma (nccRCC); Colorectal Cancer; Prostate Cancer. Primary outcome: Number of Participants With Treatment Emergent Adverse Events (TEAEs). Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-24","links":[{"label":"ClinicalTrials.gov NCT07620574","url":"https://clinicaltrials.gov/study/NCT07620574"}],"tags":["ctgov-ingest","colorectal-deep-dive"],"related":[],"cancers":["rectal-cancer","colon-cancer"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["cabozantinib","zanzalintinib","atezolizumab","nivolumab","abiraterone","prednisone","enzalutamide"],"companies":["exelixis","bms"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07620574","phase":"3","setting":"Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study","sponsor":"Exelixis","enrolled":5000,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07620574/","neighbours":{"cancer":[{"id":"colon-cancer","kind":"cancer","name":"Colon cancer (adenocarcinoma of the colon)","route":"/cancers/colon-cancer/"},{"id":"rectal-cancer","kind":"cancer","name":"Rectal cancer","route":"/cancers/rectal-cancer/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/"},{"id":"atezolizumab","kind":"drug","name":"Atezolizumab","route":"/drugs/atezolizumab/"},{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"},{"id":"prednisone","kind":"drug","name":"Prednisone","route":"/drugs/prednisone/"},{"id":"zanzalintinib","kind":"drug","name":"Zanzalintinib","route":"/drugs/zanzalintinib/"}],"company":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/"},{"id":"exelixis","kind":"company","name":"Exelixis","route":"/companies/exelixis/"}],"term":[{"id":"colorectal-trials-open-today","kind":"term","name":"Colorectal cancer trials open today (registry snapshot)","route":"/terms/colorectal-trials-open-today/"}]}}